RxDoctor Payments DataLook up a doctor →

Aamr Herekar, MD

Neurology · El Paso, TXNPI 1376741330

Payments from drug & device makers

$1,447,224in general payments, 2019–2025

Across 993 payments — averaging $1457.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$768K
  • AbbVie$235K
  • E.r. Squibb & Sons, L.L.C.$103K
  • Pfizer$72K
  • Modernatx, Inc.$53K
  • Sanofi$52K
  • plus $164K from 54 others
$30,273in research payments, 2019–2025

Across 15 payments — averaging $2018.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$18K
  • Eli Lilly$12K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly30$768,353
AbbVie(2 entities)137$235,072
E.r. Squibb & Sons, L.L.C.6$103,406
Pfizer38$72,199
Modernatx, Inc.25$52,807
Sanofi14$51,732
Bausch Health US, LLC32$43,680
SK Life Science, Inc.56$26,348
Bristol Myers Squibb4$16,752
Novartis49$15,571
Biohaven Pharmaceutical Holding Company Ltd.11$15,255
Genentech, Inc.1$12,000
Neurelis, Inc.30$11,792
Jazz Pharmaceuticals Inc.38$5,329
UCB, Inc.79$1,675
Kyowa Kirin, Inc.13$1,361
Medtronic(3 entities)22$1,314
EMD Serono, Inc.37$1,307
Biogen46$1,090
Lilly USA, LLC44$774
AstraZeneca13$769
Neurocrine Biosciences, Inc.30$744
Kedrion Biopharma, Inc.6$708
Genentech USA, Inc.29$661
Argenx US, Inc.14$582
Amgen(2 entities)21$573
Eisai Inc.13$538
Teva Pharmaceuticals USA, Inc.24$507
Lundbeck LLC14$418
Inspire Medical Systems, Inc.4$344
Harmony Biosciences LLC8$298
Octapharma USA, Inc.9$215
US Oncology Corporate, Inc.2$212
Johnson & Johnson(2 entities)10$212
Catalyst Pharmaceuticals, Inc.7$211
Immedica Pharma US, Inc.3$205
Janssen Scientific Affairs, LLC1$200
Acadia Pharmaceuticals Inc7$192
Axsome Therapeutics, Inc.8$188
Amneal Pharmaceuticals LLC4$156
ANI Pharmaceuticals, Inc.2$149
Takeda Pharmaceuticals U.S.A., Inc.1$125
Otsuka Pharmaceutical Development & Commercialization, Inc.2$113
Merz Pharmaceuticals, LLC4$109
Greenwich Biosciences, Inc.5$89
GE HealthCare4$83
Inari Medical, Inc.1$79
Averitas Pharma Inc.1$75
Banner Life Sciences, LLC3$58
Philips North America LLC1$53
Alnylam Pharmaceuticals Inc.2$53
Sunovion Pharmaceuticals Inc.3$47
GRT US Holding, Inc.3$46
Neuropace, Inc.2$45
Acorda Therapeutics, Inc2$43
Otsuka America Pharmaceutical, Inc.2$42
Ipsen Biopharmaceuticals, Inc2$35
Vanda Pharmaceuticals Inc.1$35
Cycle Pharmaceuticals Inc2$33
Impel Pharmaceuticals Inc.2$31

How this compares

$1,447,224 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$496,880
Medicare patients
612
Services billed
5,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in El Paso

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →